Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy

Chérie H. Dimph, Frank R. Dunphy, James H. Boyd, Mark A. Varvares, Han J. Kim, Val Lowe, L. Teresa, R. N. Dunleavy, Jack Rodriguez, Erin M. McDonough

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The expression of p53 protein has been reported to be in the range of 35% to 67% in head and neck squamous cell carcinoma (HNSCC). Mutations of the gene for p53 protein have been associated with rapidly proliferating tumors, and p53 protein expression has been shown to be a significant predictor of worse survival in surgically resected HNSCC. To determine whether p53 protein expression in advanced (stages III and IV) HNSCC has any impact on tumor response to 2 to 3 courses of paclitaxel (Taxol) and carboplatin, we prospectively studied prechemotherapy specimens from patients with previously untreated, advanced-stage HNSCC. We also attempted to study residual tumors after chemotherapy to determine if the p53 status of the tumor changed. Design: The expression of p53 protein was evaluated by immunohistochemical analysis (clone BP53-12-1; Bio-Genex, San Ramon, Calif). Setting: Tertiary university medical center. Intervention: Two to 3 courses of chemotherapy with paclitaxel and carboplatin. Main Outcome Measures: Pathologic complete remission or residual tumor. Results: The results of p53 immunostaining were positive in 24 (67%) of 36 HNSCC specimens before chemotherapy. After chemotherapy, 8 patients achieved pathologic complete remission. Before chemotherapy, the tumor was p53 negative in 2 patients and positive in 6 patients. Conclusions: No correlation of p53 protein expression with response to chemotherapy was noted. The expression of p53 protein converted from positive to negative in 5 (42%) of 12 specimens from patients with residual tumor after chemotherapy, with no impact on clinical outcome.

Original languageEnglish (US)
Pages (from-to)1223-1225
Number of pages3
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume123
Issue number11
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Drug Therapy
Residual Neoplasm
Paclitaxel
Proteins
Carboplatin
Neoplasms
Carcinoma, squamous cell of head and neck
Clone Cells
Outcome Assessment (Health Care)
Mutation
Survival

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Dimph, C. H., Dunphy, F. R., Boyd, J. H., Varvares, M. A., Kim, H. J., Lowe, V., ... McDonough, E. M. (1997). Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. Archives of Otolaryngology - Head and Neck Surgery, 123(11), 1223-1225.

Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. / Dimph, Chérie H.; Dunphy, Frank R.; Boyd, James H.; Varvares, Mark A.; Kim, Han J.; Lowe, Val; Teresa, L.; Dunleavy, R. N.; Rodriguez, Jack; McDonough, Erin M.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 123, No. 11, 11.1997, p. 1223-1225.

Research output: Contribution to journalArticle

Dimph, CH, Dunphy, FR, Boyd, JH, Varvares, MA, Kim, HJ, Lowe, V, Teresa, L, Dunleavy, RN, Rodriguez, J & McDonough, EM 1997, 'Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy', Archives of Otolaryngology - Head and Neck Surgery, vol. 123, no. 11, pp. 1223-1225.
Dimph, Chérie H. ; Dunphy, Frank R. ; Boyd, James H. ; Varvares, Mark A. ; Kim, Han J. ; Lowe, Val ; Teresa, L. ; Dunleavy, R. N. ; Rodriguez, Jack ; McDonough, Erin M. / Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. In: Archives of Otolaryngology - Head and Neck Surgery. 1997 ; Vol. 123, No. 11. pp. 1223-1225.
@article{9624ef25e52d4ec69e2946fd2cc62bd6,
title = "Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy",
abstract = "Background: The expression of p53 protein has been reported to be in the range of 35{\%} to 67{\%} in head and neck squamous cell carcinoma (HNSCC). Mutations of the gene for p53 protein have been associated with rapidly proliferating tumors, and p53 protein expression has been shown to be a significant predictor of worse survival in surgically resected HNSCC. To determine whether p53 protein expression in advanced (stages III and IV) HNSCC has any impact on tumor response to 2 to 3 courses of paclitaxel (Taxol) and carboplatin, we prospectively studied prechemotherapy specimens from patients with previously untreated, advanced-stage HNSCC. We also attempted to study residual tumors after chemotherapy to determine if the p53 status of the tumor changed. Design: The expression of p53 protein was evaluated by immunohistochemical analysis (clone BP53-12-1; Bio-Genex, San Ramon, Calif). Setting: Tertiary university medical center. Intervention: Two to 3 courses of chemotherapy with paclitaxel and carboplatin. Main Outcome Measures: Pathologic complete remission or residual tumor. Results: The results of p53 immunostaining were positive in 24 (67{\%}) of 36 HNSCC specimens before chemotherapy. After chemotherapy, 8 patients achieved pathologic complete remission. Before chemotherapy, the tumor was p53 negative in 2 patients and positive in 6 patients. Conclusions: No correlation of p53 protein expression with response to chemotherapy was noted. The expression of p53 protein converted from positive to negative in 5 (42{\%}) of 12 specimens from patients with residual tumor after chemotherapy, with no impact on clinical outcome.",
author = "Dimph, {Ch{\'e}rie H.} and Dunphy, {Frank R.} and Boyd, {James H.} and Varvares, {Mark A.} and Kim, {Han J.} and Val Lowe and L. Teresa and Dunleavy, {R. N.} and Jack Rodriguez and McDonough, {Erin M.}",
year = "1997",
month = "11",
language = "English (US)",
volume = "123",
pages = "1223--1225",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy

AU - Dimph, Chérie H.

AU - Dunphy, Frank R.

AU - Boyd, James H.

AU - Varvares, Mark A.

AU - Kim, Han J.

AU - Lowe, Val

AU - Teresa, L.

AU - Dunleavy, R. N.

AU - Rodriguez, Jack

AU - McDonough, Erin M.

PY - 1997/11

Y1 - 1997/11

N2 - Background: The expression of p53 protein has been reported to be in the range of 35% to 67% in head and neck squamous cell carcinoma (HNSCC). Mutations of the gene for p53 protein have been associated with rapidly proliferating tumors, and p53 protein expression has been shown to be a significant predictor of worse survival in surgically resected HNSCC. To determine whether p53 protein expression in advanced (stages III and IV) HNSCC has any impact on tumor response to 2 to 3 courses of paclitaxel (Taxol) and carboplatin, we prospectively studied prechemotherapy specimens from patients with previously untreated, advanced-stage HNSCC. We also attempted to study residual tumors after chemotherapy to determine if the p53 status of the tumor changed. Design: The expression of p53 protein was evaluated by immunohistochemical analysis (clone BP53-12-1; Bio-Genex, San Ramon, Calif). Setting: Tertiary university medical center. Intervention: Two to 3 courses of chemotherapy with paclitaxel and carboplatin. Main Outcome Measures: Pathologic complete remission or residual tumor. Results: The results of p53 immunostaining were positive in 24 (67%) of 36 HNSCC specimens before chemotherapy. After chemotherapy, 8 patients achieved pathologic complete remission. Before chemotherapy, the tumor was p53 negative in 2 patients and positive in 6 patients. Conclusions: No correlation of p53 protein expression with response to chemotherapy was noted. The expression of p53 protein converted from positive to negative in 5 (42%) of 12 specimens from patients with residual tumor after chemotherapy, with no impact on clinical outcome.

AB - Background: The expression of p53 protein has been reported to be in the range of 35% to 67% in head and neck squamous cell carcinoma (HNSCC). Mutations of the gene for p53 protein have been associated with rapidly proliferating tumors, and p53 protein expression has been shown to be a significant predictor of worse survival in surgically resected HNSCC. To determine whether p53 protein expression in advanced (stages III and IV) HNSCC has any impact on tumor response to 2 to 3 courses of paclitaxel (Taxol) and carboplatin, we prospectively studied prechemotherapy specimens from patients with previously untreated, advanced-stage HNSCC. We also attempted to study residual tumors after chemotherapy to determine if the p53 status of the tumor changed. Design: The expression of p53 protein was evaluated by immunohistochemical analysis (clone BP53-12-1; Bio-Genex, San Ramon, Calif). Setting: Tertiary university medical center. Intervention: Two to 3 courses of chemotherapy with paclitaxel and carboplatin. Main Outcome Measures: Pathologic complete remission or residual tumor. Results: The results of p53 immunostaining were positive in 24 (67%) of 36 HNSCC specimens before chemotherapy. After chemotherapy, 8 patients achieved pathologic complete remission. Before chemotherapy, the tumor was p53 negative in 2 patients and positive in 6 patients. Conclusions: No correlation of p53 protein expression with response to chemotherapy was noted. The expression of p53 protein converted from positive to negative in 5 (42%) of 12 specimens from patients with residual tumor after chemotherapy, with no impact on clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=9844256089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844256089&partnerID=8YFLogxK

M3 - Article

C2 - 9366702

AN - SCOPUS:9844256089

VL - 123

SP - 1223

EP - 1225

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 11

ER -